Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA Technologies reported approximately $3 million in international sales of oral TPOXX® for Q1 2021 and an additional $7 million in April 2021. The company noted a total revenue of $4.8 million, improving from $2.6 million in Q1 2020, highlighting a shift in sales concentration. Concurrently, SIGA repurchased 1 million shares for $6.5 million. The pandemic has not materially affected liquidity but may influence future contract awards. A conference call is scheduled for today at 4:30 PM ET to discuss these updates.
SIGA Technologies has filed a New Drug Application (NDA) with the FDA for an intravenous (IV) formulation of TPOXX to treat smallpox in adults and pediatric patients over 13 kg. This marks a significant step in expanding treatment options for patients unable to swallow oral capsules, particularly relevant amid the ongoing COVID-19 pandemic. The IV formulation leverages data from prior studies, eliminating the need for additional trials. TPOXX is the first approved smallpox antiviral, and SIGA aims to facilitate access for a broader patient population in emergencies.
SIGA Technologies, Inc. (SIGA) announced a webcast and conference call scheduled for May 6, 2021, at 4:30 P.M. ET to provide a business update. CEO Phil Gomez and CFO Daniel Luckshire will participate. SIGA specializes in health security, primarily focusing on countermeasures against biological threats. Its lead product, TPOXX®, is a treatment for smallpox, with the US holding a stockpile of 1.7 million treatment courses. The company signed a potentially $600 million contract with BARDA in 2018 for TPOXX® development and procurement.
On March 23, 2021, Cipla Therapeutics and SIGA Technologies announced a strategic partnership aimed at addressing antimicrobial resistance (AMR). With AMR identified as a top global health threat by the WHO, this collaboration seeks to leverage Cipla's antibiotic expertise and SIGA's drug development skills to deliver innovative solutions to the Biomedical Advanced Research and Development Authority (BARDA). The partnership will enhance U.S. health security by providing access to novel antibacterial drugs, notably Cipla's ZEMDRI®. The deal aligns with both companies' commitment to countering AMR and improving public health.
SIGA Technologies reported strong financial results for 2020, delivering approximately 363,000 courses of oral TPOXX® to the U.S. government, generating $113 million in revenue. In Q4 alone, revenues reached $37.8 million, compared to $26.8 million in Q4 2019. The company also secured international contracts worth up to $47 million, including a $33 million contract from Canada's Public Health Agency. Despite the challenges posed by the COVID-19 pandemic, SIGA's financial position remains stable. A conference call is scheduled for March 4, 2021, to discuss these developments.
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on March 4, 2021, at 4:30 PM ET to provide a business update. The call will feature CEO Dr. Phil Gomez, CFO Daniel Luckshire, and CSO Dr. Dennis Hruby. Participants can join the live webcast on SIGA's website, with a replay available for two weeks. SIGA focuses on health security, particularly through its lead product, TPOXX, an antiviral drug for smallpox. The company maintains a stockpile of 1.7 million doses in the Strategic National Stockpile.
SIGA Technologies (SIGA) announced a significant contract with the Public Health Agency of Canada for the purchase of oral TPOXX® valued at up to $33 million over five years. The initial commitment includes $3.4 million by March 31, 2021, and a cumulative $17.2 million by March 31, 2023. This contract follows a previous $14 million agreement with the Canadian Department of National Defence. SIGA expects Canadian regulatory approval for TPOXX in late 2021 or early 2022, enhancing its role in biodefense and public health preparedness.
On November 12, 2020, SIGA Technologies (SIGA) announced Dr. Dennis Hruby's participation in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference. The discussion, titled “COVID-19: Insights on an Epidemic Outbreak,” is scheduled for November 13, 2020, highlighting the importance of health security amidst the ongoing pandemic. Dr. Hruby emphasized the significance of TPOXX® (tecovirimat), an antiviral drug for smallpox, as a countermeasure against potential future pandemics. SIGA maintains a stockpile of 1.7 million TPOXX® courses under Project BioShield.
In Q3 2020, SIGA Technologies (SIGA) delivered approximately 134,000 courses of TPOXX® to the U.S. government, generating revenue of $41.4 million. Total revenues for Q3 were $44.3 million, a 35% increase compared to $32.9 million in Q3 2019. The company also reported net income of $31.6 million or $0.31 per share. Additionally, Canada plans to purchase up to 33,300 courses of TPOXX® over five years. SIGA repurchased 0.9 million shares for $5.6 million, totaling 3.7 million shares repurchased in 2020.
SIGA Technologies, Inc. (SIGA) will host a business update conference call on November 5, 2020, at 4:30 PM ET. CEO Dr. Phil Gomez and CFO Daniel Luckshire will present. A live webcast will be accessible via SIGA's website, and a replay will be available for two weeks. SIGA focuses on health security, with its leading product TPOXX® for smallpox treatment, approved by the FDA in July 2018. The U.S. government maintains a stockpile of 1.7 million courses under Project BioShield. For more details, visit www.siga.com.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
